Health and Biomedical Innovation, UniSA Clinical and Health Sciences, University of South Australia, Adelaide, 5000, Australia.
Health and Biomedical Innovation, UniSA Clinical and Health Sciences, University of South Australia, Adelaide, 5000, Australia.
Mutat Res Rev Mutat Res. 2021 Jan-Jun;787:108372. doi: 10.1016/j.mrrev.2021.108372. Epub 2021 Feb 17.
Micronucleus (MN) assay has been widely used as a biomarker of DNA damage, chromosomal instability, cancer risk and accelerated aging in many epidemiological studies. In this narrative review and meta-analysis we assessed the association between lymphocyte micronuclei (MNi) and cancers of the skin, blood, digestive tract, and prostate. The review identified nineteen studies with 717 disease subjects and 782 controls. Significant increases in MRi for MNi were observed in the following groups: subjects with blood cancer (MRi = 3.98; 95 % CI: 1.98-7.99; p = 0.000) and colorectal cancer (excluding IBD) (MRi = 2.69; 95 % CI: 1.82-3.98, p < 0.000). The results of this review suggest that lymphocyte MNi are a biomarker of DNA damage and chromosomal instability in people with haematological or colorectal cancers. However, the MRi for lymphocyte MNi in subjects with cancers of skin, prostate, esophagus was not significantly increased. More case-control and prospective studies are warranted to further verify the observed trends and to better understand the role of lymphocyte MNi as a biomarker of cancer risk in blood, skin, digestive tract and prostate.
微核（MN）试验已被广泛应用于许多流行病学研究中，作为 DNA 损伤、染色体不稳定性、癌症风险和加速衰老的生物标志物。在本综述和荟萃分析中，我们评估了淋巴细胞微核（MNi）与皮肤癌、血液癌、消化道癌和前列腺癌之间的关联。本综述共确定了 19 项研究，涉及 717 名疾病患者和 782 名对照。以下研究组中观察到 MNi 的 MRi 显著增加：血液癌患者（MRi=3.98；95%CI：1.98-7.99；p=0.000）和结直肠癌（不包括 IBD）（MRi=2.69；95%CI：1.82-3.98，p<0.000）。本综述的结果表明，淋巴细胞 MNi 是血液系统或结直肠癌患者 DNA 损伤和染色体不稳定性的生物标志物。然而，皮肤癌、前列腺癌、食管癌患者的淋巴细胞 MNi 的 MRi 没有显著增加。需要更多的病例对照和前瞻性研究来进一步验证观察到的趋势，并更好地理解淋巴细胞 MNi 作为血液、皮肤、消化道和前列腺癌风险生物标志物的作用。
